Explore vaccine recommendations made before conception, reported reproductive concerns, product ingredients, individual susceptibility and questions to ask before you decide.
Exploiting Women and Children in Vaccine ExperimentsRead the Full Commentary with References & Leave a Comment →
You are thinking about having a baby. Maybe not tomorrow, but soon enough that you are being more careful about what goes into your body, what you eat and drink, the air you breathe, environmental exposures and other factors that could affect your fertility. You are also thinking about what you want to know before becoming pregnant.
One topic your doctor may bring up is vaccination. You may be asked whether you are “up to date” on recommended vaccines and encouraged to receive one or more before trying to conceive. Some vaccines are not recommended after pregnancy begins; others may be discussed before, during or after pregnancy depending on your age, health history, previous vaccinations and individual risk factors.
Before deciding about getting vaccinated before you become pregnant, consider asking your health care provider what is known about the effects of the specific vaccine being recommended on ovarian function, conception, miscarriage and early fetal development. What reproductive studies were conducted, and were they conducted in animals or humans? How many animals or women were studied? How long were they followed for vaccine reaction symptoms, injuries or deaths? What has been reported or published about safety and effectiveness since licensure of the vaccine(s) you are being encouraged to get, and what questions remain unanswered?
The time to investigate these questions is before you are pregnant. You can identify the exact vaccine product being recommended, review the manufacturer’s product information package insert, consider your personal and family health history, and make an informed, voluntary decision without the pressure of an immediate prenatal appointment. Informed consent to medical risk-taking is a natural right, and a recommendation should begin a discussion, not end it.
IMPORTANT NOTE: Federal health officials and medical trade groups do not always agree on vaccine policy for women who are pregnant or planning to get pregnant. CDC website pages may also present different language around recommended pre-natal or pregnancy vaccines. The provider guidance table on the CDC’s website lists COVID-19 vaccination during pregnancy as “No guidance/not applicable,” while the CDC’s public-facing pregnancy web page describes a 2026–2027 COVID-19 vaccine recommendation for adults and identifies pregnancy as a risk factor for complications.
Your doctor may choose to follow federal vaccination policy, a medical trade group recommendation, state health department guidance or another institutional vaccine policy. You can ask which recommendation is being used, identify the exact vaccine product, and review the current manufacturer product information package insert before making a decision.
Learn more: CDC Guidelines for Vaccinating Pregnant Women · CDC Vaccine Recommendations Before During and After Pregnancy · Vaccination During Pregnancy: Is It Safe? (video & references)
A federal vaccine recommendation is often a starting point for discussion with your doctor about vaccination before or during pregnancy. A population-based recommendation does not determine whether a particular vaccine is appropriate for every individual woman. You can ask why a vaccine is being recommended for you; review the complications of the disease being targeted; identify the exact manufacturer’s vaccine product, and the ingredients, contraindications, precautions and published evidence about positive or negative health effects in women vaccinated before, during or after pregnancy.
For more information about the diseases discussed here and their vaccines, explore the NVIC Vaccine and Disease Library.
Select a vaccine to see what federal guidance says and what NVIC wants you to know.
CDC recommends measles, mumps and rubella (MMR) vaccination before pregnancy for women without laboratory evidence of immunity, particularly immunity to rubella and measles. MMR is a live-virus vaccine and is not given during pregnancy. CDC advises avoiding pregnancy for 28 days after MMR vaccination.
If you received several MMR doses as a child, ask what evidence is being used to determine whether you need another dose and whether your vaccination record or laboratory testing of measles, mumps and rubella titers answers that question. The risks of the three diseases, the reported side effects and effectiveness of the combined MMR vaccine, contraindications and precautions/warnings are all relevant to the discussion.
Varicella zoster (chickenpox) vaccine is a live-virus vaccine and is not given during pregnancy. If you have no evidence of immunity, your history of chickenpox or prior vaccine doses and titer laboratory results may affect the recommendation. If vaccination is discussed and you want to be vaccinated before conception, confirm the number and timing of doses and the recommended time interval to wait before trying to become pregnant.
If you are considering getting another dose of chickenpox vaccine, discuss your history of chickenpox, prior doses of chickenpox vaccine and any laboratory testing that has measured your titers (antibody levels) to varicella zoster with your health care provider. You can ask for the name of the manufacturer’s product and review the current manufacturer package insert, as well as consider how the timing of doses of chickenpox vaccine and the recommended waiting period before conception fit with your conception plans.
Human papillomavirus (HPV) vaccine is not recommended during pregnancy. If you begin the two- or three-dose HPV vaccination series and then become pregnant, the CDC advises delaying remaining doses until after pregnancy. Because HPV vaccination may be discussed before conception, questions about the exact manufacturer’s product, pregnancy labeling, reproductive studies that have been conducted and reports of serious reactions, including ovarian failure problems, are relevant.
The first HPV vaccine to be licensed in the U.S. (in 2006) was Merck’s Gardasil, containing four strains of HPV, including two strains which are most associated with sexually transmitted HPV-related cervical cancers, as well as two strains associated with genital warts. In 2020, Merck received a license for Gardasil 9, which contains 5 additional HPV strains targeting HPV infection-associated head and neck cancers, and it replaces Gardasil 4.
For women who received the two or three shot Gardasil 4 series, there is no official recommendation to get revaccinated with Gardasil 9. Although some doctors may recommend revaccination, it is advisable to investigate the safety and effectiveness of revaccination with Gardasil 9 before making a decision.
NVIC’s HPV information page discusses not only reports of HPV vaccine-related brain and immune dysfunction but also reports of premature ovarian failure following Gardasil vaccination. As of August 28, 2026, the federal Vaccine Adverse Event Reporting System (VAERS) contained 82,148 HPV vaccine adverse event reports, including 650 deaths, 8,378 hospitalizations and 3,966 disabling conditions.
VAERS reports document adverse events occurring after vaccination and can identify safety signals. An adverse reaction report to VAERS alone cannot establish causation, but reported vaccine adverse event signals warrant taking the time to learn more.
Gardasil 9 contains 500 micrograms of aluminum supplied as an amorphous aluminum hydroxyphosphate sulfate adjuvant. Gardasil 9 also contains 50 micrograms of polysorbate 80 and other ingredients. The manufacturer product information package insert states that there are no adequate and well-controlled studies of Gardasil 9 in pregnant women. It also describes animal studies that did not find effects on female fertility.
COVID-19 vaccine recommendations for women who are pregnant or planning pregnancy have changed since 2025. CDC’s professional pregnancy guidance table on the CDC website currently lists COVID-19 as “No guidance/not applicable.” However, some doctors and medical trade groups have made statements that they will continue to recommend COVID-19 shots before or during pregnancy.
NVIC has submitted public comments to the government expressing concern about the lack of good scientific evidence for the safety of giving mRNA COVID-19 shots to women who are pregnant. Before conception, questions you may want to ask include which manufacturer’s COVID vaccine product is being offered; what vaccine recommendations the health care provider follows; what reproductive and pregnancy studies say about administration of COVID shots before or during pregnancy, and what is known about the distribution of biochemically modified mRNA and the synthetic spike protein in the body or other potential biological activity effects on immune and brain function.
Your doctor may also discuss administering hepatitis B, influenza and Tdap (tetanus, diphtheria and acellular pertussis) vaccines before conception depending on your age, medical history, previous vaccination and risk factors. The CDC recommends hepatitis B vaccine for women before conception or during pregnancy if they have not previously been given a hepatitis B shot. Tdap is recommended during every pregnancy, preferably between weeks 27 and 36, to protect the mother and newborn from whooping cough, even if you received a dose before becoming pregnant.
Questions you may want to ask include why a vaccine is being discussed before conception, especially if another dose may be recommended after pregnancy begins, and which vaccine trade name, manufacturer, formulation and ingredients are involved. Vaccine products targeting the same disease can contain different adjuvants, preservatives and residual ingredients from the manufacturing process.
It is also important to discuss with your health care provider the scientific evidence that it is safe and effective to give multiple vaccines on the same day to a woman, especially during pregnancy.
A preconception visit with your health care provider discussing vaccines should involve more than checking boxes on an adult vaccination schedule. Bring your vaccination records and make sure the person recommending vaccination knows your reproductive and personal and family medical history.
The word vaccine describes a category, not one formulation. Ask for the vaccine’s trade name, manufacturer name and current manufacturer information package insert before you decide. Do not rely on verbal assurances that every vaccine product produced by different manufacturers targeting the same disease is identical.
Merck’s Gardasil 4 vaccine was fast-tracked to licensure in 2006 and aggressively promoted for use by adolescent girls and young women. Immediately after it was licensed, NVIC’s co-founder and president Barbara Loe Fisher issued an NVIC press release questioning the adequacy of prelicensure testing in young girls; the use of an aluminum-containing comparator instead of a true placebo in clinical trials of Gardasil; the simultaneous administration of hepatitis B and Gardasil to trial participants; the unexplained dismissal of injuries and deaths that occurred in the trial by principal investigators as unrelated to the vaccine, and the fast tracking of Gardasil without adequate investigation of adverse events.
NVIC June 27, 2006 Press Release: Merck’s Gardasil Not Proven Safe for Little Girls
Questions about HPV vaccine prior to conception matter because premature ovarian failure, now often called primary ovarian insufficiency or POI, has been reported after HPV vaccination. Ovarian function directly affects whether and when a woman can conceive.
Published case reports and case series have described adolescents and young women who developed not only immune and neurological disorders but also reported menstrual irregularities, amenorrhea and POI following quadrivalent HPV vaccination. These reports document serious health problems and identify signals for further study; they cannot by themselves determine causation.
NVIC’s current HPV page also identifies premature ovarian failure among adverse events reported following Gardasil vaccination. While it is illogical to assume every adverse event report was caused by a recently administered HPV vaccine, it is equally illogical to assume that reported adverse events are never caused by a government licensed and recommended vaccine like Gardasil.
A nationwide Danish cohort followed 996,300 girls and women ages 11 to 34 and did not find a statistically significant association between quadrivalent HPV vaccination and diagnosed POI. The study identified 144 POI diagnoses during follow-up, including 54 among vaccinated individuals. The authors concluded that vaccination was unlikely to be associated with a moderate or large increase in diagnosed POI, while acknowledging the rarity of the condition and the limitations of observational research.
For informed consent, both parts of the published data and public record matter. Serious reproductive problems have been reported and published in case reports, while a much larger population study did not find an increased rate of diagnosed POI.
However, the population study does not address the possibility that a biologically susceptible individual can experience a vaccine-related reproductive injury.
The current FDA package insert states that each 0.5 mL dose of Gardasil 9 covering nine strains of the HPV virus contains approximately 500 micrograms of an aluminum adjuvant (amorphous aluminum hydroxyphosphate sulfate); 50 micrograms of polysorbate 80; sodium chloride; L-histidine; sodium borate; residual yeast protein and water. The product does not contain a preservative or antibiotics.
The Merck product information package insert states that adequate and well-controlled studies of Gardasil 9 vaccine given to pregnant women have not been conducted, although it describes prelicensure pregnancies and animal reproductive studies, including animal findings, that did not show effects on female fertility. It also states that Gardasil 9 has not been evaluated for carcinogenicity, genotoxicity or impairment of male fertility.
A woman may enter pregnancy believing she is already up to date on tetanus and pertussis vaccination. Federal policy recommends a Tdap dose during every pregnancy, preferably during gestational weeks 27 through 36, regardless of when a previous Tdap dose was received.
That means a woman who receives Tdap shortly before conception may still be offered another Tdap dose later in the same pregnancy. If a routine tetanus and pertussis-containing booster is proposed while you are trying to conceive, ask whether it is medically necessary at that time and how the dose relates to the Tdap dose you may be offered during pregnancy.
The CDC recommends that adults get a dose of tetanus vaccine every 10 years.
FDA lists Boostrix as indicated for booster immunization in people age 10 years and older and for use between weeks 27 and 36 of pregnancy to prevent pertussis in infants younger than two months. The current label includes information on a pregnancy registry and observational data. Consider whether trial participants were given Tdap vaccine during weeks 27 through 36 of pregnancy and how health outcomes were measured and whether the data was made part of the manufacturer’s label.
COVID-19 shots have generated intense scrutiny about fertility because experimental mRNA technology was used at population scale and distributed under an Emergency Use Authorization (EUA) promoting use by women of childbearing age before long-term fertility and reproductive outcomes were adequately studied and understood by the women who were being vaccinated. Several different questions became blended together online, such as antibody cross-reactivity; potential distribution and storage of lipid nanoparticle components in body tissues and organs; menstrual changes; and questions about ovarian reserve, implantation, miscarriage and birth defects.
One proposed hypothesis was that antibodies to the synthetic SARS-CoV-2 spike protein in COVID shots might cross-react with syncytin-1, a human protein involved in placental development, and affect implantation or pregnancy outcomes.
Published studies listed below did not find evidence supporting that proposed mechanism. A 2022 study did not find increased anti-syncytin-1 antibodies after vaccination, and a small frozen embryo transfer study found no difference in implantation or sustained implantation.
Among vaccine-seropositive, infection-seropositive and seronegative women, the failure to scientifically demonstrate this proposed biological mechanism does not answer every COVID vaccine reproductive safety question. However, syncytin-1 cross-reactivity currently should not be presented as established fact.
Concern also arose from preclinical rat biodistribution data associated with the Pfizer’s BNT162b2 Comirnaty COVID biological. The data showed that radiolabeled lipid nanoparticle components delivering synthetic mRNA into the cells of the body did not remain exclusively at the injection site and were detected in other tissues and organs, including ovaries.
Detection of a labeled lipid nanoparticle component in ovarian tissue is not proof of ovarian injury, infertility or damage to eggs. However, it raises specific questions about exactly what was detected, at what concentration, for how long, and whether any reproductive effects were observed in ovarian tissue, oocytes, hormones, fertility or future pregnancies.
Menstrual-cycle changes have been reported and studied following COVID-19 vaccination. A temporary change in cycle timing or bleeding pattern is not automatically the same as infertility or diminished ovarian reserve. At the same time, reports from women should not be dismissed simply because the biological mechanism is uncertain or the changes are described as temporary.
Published fertility and assisted-reproduction studies generally have not found reduced oocyte yield, fertilization, embryo quality, implantation or reduced pregnancy rates after COVID vaccination. Longer follow-up is still needed to evaluate reproductive outcomes after women receive COVID shots that may take years to identify and for women with genetic or biological susceptibilities to be identified.
Pregnancy outcomes must be evaluated by vaccine product, dose, timing and trimester. Studies limited to live births can miss pregnancy losses, and a study finding no increase in overall birth defects may still require examination of individual outcomes and potentially vulnerable subgroups in populations.
The Vaccine Reaction journal newspaper has reported several findings that merit careful review alongside the underlying studies. A Czech population study reported an association between prior COVID-19 vaccination and lower rates of successful conception, defined by the study as pregnancies resulting in live births. Because the study was observational and did not measure every early loss or failed implantation, it raises a question for further research but does not establish that vaccination caused reduced fertility. (Read the report)
A separate Israeli retrospective cohort study, first reported as a preprint, described an association between mRNA COVID-19 vaccination during weeks eight and 13 of pregnancy and later miscarriage. The report itself noted possible confounding and other limitations. The underlying study should be reviewed before any conclusion is drawn. The finding is not proof that COVID shots cause miscarriage.
The Vaccine Reaction also reported on 2021 private email messages in which senior federal health officials discussed the existence of limited pregnancy data and a theoretical concern that fever or a strong inflammatory response after a second dose of an mRNA COVID shot might contribute to miscarriage in the first trimester. Those email messages among public health officials do not establish that COVID shots cause miscarriage. However, they do raise an informed-consent question: what uncertainties about COVID-shot induced inflammation in the first trimester and concerns about potential miscarriage were known among senior health officials in 2021, what kind of vaccine risk information was communicated to pregnant women, and were they given enough information to make an informed and voluntary vaccination decision? (Read the report)
The findings of a 2026 Iranian vaccine registry-based cohort study, reported by The Vaccine Reaction, also described a higher incidence of congenital anomalies among infants born to women given a COVID shot during the first trimester compared with unvaccinated women or those vaccinated later. This finding needs review of the original paper, outcomes, study design and possible confounding. It is a reported association requiring investigation, but not conclusive proof of causation. (Read the report)
The word “vaccine” describes a biological product category, not one formulation. Vaccine ingredients and use indications can differ by product and manufacturer, including the number of recommended doses, and recommended ages and timing of administration.
Aluminum salt adjuvants are used to stimulate strong immune responses and are present in inactivated vaccines, such as Gardasil 9, hepatitis B vaccine and some Tdap products. Gardasil 9 contains approximately 500 micrograms of aluminum as amorphous aluminum hydroxyphosphate sulfate per dose. Aluminum is a known neurotoxin and you could ask your health care provider about what kind of reproductive toxicology has been conducted on aluminum containing vaccine adjuvants.
Polysorbate 80 is an excipient in Gardasil 9 and other vaccine products. It is a surfactant and solubilizing agent that researchers have found can break through the blood brain barrier. Animal toxicology findings at high experimental doses cannot be directly converted into risks for humans, but women should still be able to ask what studies were performed using the amount and formulation in the product being offered.
Formaldehyde may be used during manufacture of certain inactivated vaccines and can remain in residual amounts. It is not present in every vaccine. Ask whether the recommended vaccine contains residual formaldehyde, how much the manufacturer lists and what reproductive or pregnancy data exist for that product.
Thimerosal is an ethylmercury-containing preservative that may still be used in some multidose influenza vaccine presentations. Mercury is a known neurotoxin. Women who want to avoid thimerosal can ask which influenza product is being offered and whether a single-dose preservative-free formulation is available.
Planning pregnancy is also a time to identify environmental exposures unrelated to vaccination. Exposures to lead, mercury, cadmium and arsenic can affect reproductive health and fetal development. CDC and NIOSH identify lead and other metals as workplace reproductive hazards, and recent studies have examined associations between arsenic, cadmium, mercury and measures of ovarian reserve.
Lead, methylmercury, cadmium, arsenic and aluminum are different exposures. Each one requires review of evidence relevant to its chemical form, amount and route of administration.
Vaccine policies are population based and cannot account for every genetic, epigenetic, environmental or other biological factor that may affect an individual’s response to an infectious disease or vaccination.
When planning pregnancy, review whether you or a close family member have experienced a serious vaccine reaction; have an autoimmune or neurological disorder or severe allergies; is predisposed to mounting hyperactive inflammatory responses (mast cell activation); or has a history of infertility, ovarian dysfunction, recurrent miscarriage or another condition that could affect the immune responses inherent during pregnancy.
Vaccine reaction symptoms and chronic health problems that begin after vaccination are real experiences worth documenting and evaluating, even as their cause may not be immediately known and is in the process of being assessed.
A population based study can estimate average risk in a certain population but cannot predict with certainty how you, as an individual, will respond to a particular vaccine or infectious disease.
A question for further study of maternal vaccination policies is whether the type, magnitude and timing of the inflammatory response elicited by a particular vaccine could affect conception or early pregnancy in a biologically susceptible woman.
Evidence that chronic or severe inflammation can affect reproductive health does not, by itself, establish that a short-term inflammatory response after vaccination causes infertility or miscarriage. However, women with a chronic inflammatory condition or history of mounting hyper-inflammatory responses to immune system stimulation, which can affect how inflammation resolves in the body after vaccination, may want to discuss what is known about the specific vaccine product. Product-specific reproductive and pregnancy data are important to that discussion.
NVIC has a history of publicly questioning policies that atypically manipulate the immune system of healthy pregnant women and their unborn babies with vaccines without high-quality evidence proving safety and effectiveness.
A recommendation made for millions of women cannot replace a review of your personal and family health and reproductive history, prior vaccine reactions, and personal genetic, epigenetic and biological susceptibilities to complications from vaccination or infections.
Vaccine products contain different ingredients and are manufactured using different production methods. Learn about the differences among brands, formulations, dosing, timing, or combination of vaccines bundled together being recommended for you.
NVIC has a long record of questioning policies that pressure women to accept vaccination before or during pregnancy without adequate evidence, full disclosure and respect for informed consent. NVIC co-founder and president Barbara Loe Fisher has argued that evidence standards for licensing and policymaking should be especially high when vaccines are intended for pregnant women and their unborn babies, and that women must be free to make voluntary decisions without coercion or sanctions for declining to adhere to government or medical trade vaccine policy recommendations.
In a recent commentary in The Vaccine Reaction journal newspaper, Barbara Loe Fisher revisits reports about experimental tetanus vaccine containing hCG in campaigns involving women of childbearing age, and the history of experimental high-potency measles vaccine experiments involving infants. The questions those histories raise—what product was given, what was known about it, and whether childbearing women and parents of infants were given informed consent—belong in today’s discussion of vaccination before and during pregnancy.
Read the full commentary and its references: Exploiting Women and Children in Vaccine Experiments
The preconception period gives you time to find out whether an obstetrician, midwife, hospital or birthing center respects your right to exercise informed consent to medical risk taking and how the practice handles patient decisions that differ from its preferred vaccine-use policy.
Knowing the answers before pregnancy or labor can help you prepare before you are required to make a decision during active labor.
You have the right to information about benefits, risks and alternatives, to ask questions, and to make a voluntary decision without coercion, threats or sanctions.
Federal health agency guidance advises avoiding pregnancy for 28 days after MMR and for one month after each varicella zoster (chickenpox) vaccine dose. Other vaccine products have different indications. Identify the exact product and manufacturer and verify current recommendation guidelines before deciding when to try to conceive.
Review the vaccine product, timing of doses, manufacturer product information package insert and current federal agency or medical trade group guidance with a qualified health professional. Live-virus vaccines are contraindicated during pregnancy and have specific waiting-periods before conception.
You can ask why a vaccine is being recommended for you, request the manufacturer product information package insert and discuss your individual risk factors with your health care provider. A provider recommendation is not the same as a legal requirement. Informed consent rights include the freedom to accept, decline or delay a medical procedure that carries a risk of injury or death, such as vaccination.
Ask your health care provider to document your question and the response in your medical record. Request the evidence relied upon, including studies of the exact vaccine product and reproductive outcomes in clinical trials. If your questions are ridiculed or ignored, consider finding another health care provider who does respect your informed consent rights.
Federal health agency guidance advises delaying remaining HPV doses until after pregnancy. MMR and varicella vaccines are contraindicated during pregnancy, but inadvertent vaccination with MMR and varicella vaccines is not considered by the CDC to be a reason to terminate a pregnancy. Contact your health care provider and review the exact vaccine product indications.
Recommendations for vaccines during pregnancy may include influenza, Tdap, RSV, hepatitis B and COVID-19, depending on the vaccine policy recommendations your doctor follows. Continue to the I’m Pregnant Right Now page for information about vaccines discussed during pregnancy.
Vaccination During Pregnancy: Is It Safe? (video & references)
Seek appropriate medical care and document the product name, manufacturer, lot number, timing and symptoms of the reaction. Suspected reactions can be reported to the federal Vaccine Adverse Event Reporting System (VAERS). A VAERS report does not file a vaccine injury claim in the federal Vaccine Injury Compensation Program (VICP), which has deadlines for claimants to apply.
This educational content is not individualized medical advice. Vaccine use recommendations, vaccine product labeling, state vaccine mandates and medical facility policies may change. Before you make a decision about vaccination, verify the current information for the exact vaccine product being recommended and the personal circumstances affecting your decision.